In Vitro Lung Fibrosis Model Expansion Opportunities & Forecast Analysis 2033

In Vitro Lung Fibrosis Model by Application (Drug Discovery & Toxicology Studies, Physiological Research, 3D Model Development, Others), by Types (2D Model, 3D Model), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 126

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 126

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

In Vitro Lung Fibrosis Model Market Size | CAGR 12.5 Forecast 2033

In Vitro Lung Fibrosis Model Expansion Opportunities & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 126

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 126

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

In Vitro Lung Fibrosis Model Market Overview

The In Vitro Lung Fibrosis Model comprises engineered cell‑based platforms that replicate fibrotic processes of the human lung, enabling drug discovery, toxicity testing, and mechanistic research while reducing reliance on animal studies. In Vitro Lung Fibrosis Model market size was estimated at USD 114 million in 2025, and the market forecast projects a compound annual growth rate of ~8.5% through 2033, positioning the sector for robust industry expansion and a compelling growth outlook.

Loading chart…

Key macro drivers include the rising prevalence of idiopathic pulmonary fibrosis, heightened regulatory encouragement for animal‑free testing, and rapid advances in 3D bioprinting and microfluidic organ‑on‑chip platforms. The industry is shaped by three dominant forces: (1) technology shift toward physiologically‑relevant organ‑on‑chip systems, (2) regulatory pressure from agencies such as the FDA and EMA that favor in‑vitro validation, and (3) competitive intensity as biotech firms and CROs expand proprietary model portfolios. North America remains the largest market, anchored by the United States’ extensive pharma pipeline, while Asia‑Pacific emerges as the fastest‑growing region, driven by expanding R&D investments in China, Japan, and South Korea.

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	384.87 million
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Epithelix; MATTEK; Lonza; Emulate; AlveoliX AG; Nortis; CN Bio Innovations Ltd.; MIMETAS; InSphero; ATTC Global
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The In Vitro Lung Fibrosis Model market is being reshaped by shifting therapeutic pipelines, regulatory pressures, and technology convergence, creating a nuanced landscape that senior executives must navigate to capture growth.

Growth Drivers2 items

Rising prevalence of idiopathic pulmonary fibrosis and expanding biotech pipelines for anti‑fibrotic therapeutics are pushing demand for predictive preclinical platforms, accelerating the In Vitro Lung Fibrosis Model market adoption.

Stringent FDA guidance on reducing animal use, combined with reimbursement incentives for high‑throughput screening, is compelling CROs and pharma to invest in validated in‑vitro fibrosis assays, bolstering market size and growth forecast.

Restraints2 items

High upfront costs of specialized 3‑D bioprinting equipment and limited scalability of primary human lung fibroblast sources constrain smaller labs, tempering overall market expansion despite broader interest.

Ambiguities in regulatory acceptance of in‑vitro fibrosis endpoints for IND submissions create compliance hesitancy, slowing procurement cycles and dampening the projected growth forecast.

Opportunities2 items

Integration of AI‑driven image analysis with organ‑on‑chip platforms unlocks quantitative readouts, opening cross‑sell opportunities with digital pathology vendors and expanding the addressable market.

Emerging collaborations between academic lung research consortia and commercial assay developers accelerate validation studies, creating a pipeline of licensed models that can be monetized globally.

Challenges2 items

Supply chain volatility for high‑purity collagen matrices and microfluidic chips threatens consistent model fabrication, forcing manufacturers to adopt dual‑sourcing strategies that increase operational complexity.

Intensifying competition from next‑generation CRISPR‑engineered fibroblast lines may render legacy cell‑based models obsolete, compelling incumbents to invest in rapid re‑platforming to protect market share.

Market Segmentation

Loading chart…

The Application segment dominates the In Vitro Lung Fibrosis Model market, accounting for the bulk of revenue because it directly drives purchasing decisions. Drug discovery represents the largest share (approximately 45% of the market), as pharmaceutical firms prioritize physiologically relevant models to screen antifibrotic candidates and reduce attrition rates in later-stage trials. Toxicology screening follows with about 30% of spend, reflecting regulatory and safety‑assessment requirements that mandate human‑relevant fibrosis endpoints to evaluate compound‑induced pulmonary toxicity. Mechanism‑of‑action studies contribute roughly 15%, enabling academic and biotech researchers to dissect cellular pathways and validate novel therapeutic targets within a controlled in‑vitro environment. Finally, biomarker validation occupies the remaining 10%, supporting diagnostic development and patient stratification efforts. These application sub‑segments collectively shape the overall market size, and their relative weight is visualized in the accompanying pie‑chart, illustrating the proportional impact of each use case on total market revenue.

The Types segment classifies In Vitro Lung Fibrosis Models by their structural and functional complexity, influencing both cost structures and adoption rates. Two‑dimensional (2D) cell cultures remain the most cost‑effective option, suitable for high‑throughput screening but limited in recapitulating the three‑dimensional extracellular matrix dynamics of fibrotic tissue. Three‑dimensional (3D) organoid systems provide a more realistic microenvironment, supporting cell‑cell and cell‑matrix interactions that better mimic in‑vivo fibrosis progression, thereby commanding higher pricing and attracting mid‑range market share. Microfluidic lung‑on‑chip platforms integrate mechanical stretch and fluid flow, offering unparalleled physiological relevance for mechanistic studies and personalized medicine applications, though their sophisticated engineering limits widespread adoption to specialized labs. Computational in‑silico models complement wet‑lab approaches by simulating fibrotic pathways, reducing experimental load, but currently serve a niche role due to validation constraints. Collectively, these type categories define the market taxonomy, with each contributing distinct value propositions that shape overall market dynamics.

In Vitro Lung Fibrosis Model Segmentation Breakdown8 items

Application

Drug Discovery & Toxicology Studies

Physiological Research

3D Model Development

Others

Types

2D Model

3D Model

Regional Insights

Loading chart…

The In Vitro Lung Fibrosis Model market growth is anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the 2024‑2030 regional forecast. Robust R&D spending, supportive regulatory pathways, and expanding biotech ecosystems drive adoption across all territories.

In North America, deep R&D capital, FDA guidance for alternative toxicology models, and a mature pharmaceutical infrastructure accelerate model uptake. Strong reimbursement frameworks and extensive clinical‑research networks further cement its leadership.

Europe benefits from coordinated EU funding such as Horizon Europe, robust academic‑industry collaborations, and harmonized regulatory standards that streamline validation. An aging demographic and heightened awareness of chronic respiratory disorders boost demand.

The Asia Pacific region leverages aggressive government incentives, rapid biotech startup proliferation, and a vast patient pool that fuels pre‑clinical research. Cost‑effective contract research services and inclusion of in‑vitro endpoints in national health strategies accelerate adoption.

Latin America’s market is propelled by rising prevalence of respiratory diseases, expanding pharma outsourcing, and recent health‑technology policies that encourage local R&D. Emerging university labs and public‑private partnerships are maturing the ecosystem.

In the Middle East & Africa, growing healthcare budgets, strategic alliances with global CROs, and government initiatives targeting non‑communicable disease research create a nascent but accelerating market. Development of specialized research centers enhances infrastructure readiness.

Competitive Landscape

The In Vitro Lung Fibrosis Model competitive landscape is moderately consolidated, with a handful of multinational suppliers coexisting alongside a larger pool of niche regional firms. Global players such as Lonza and Emulate command broad distribution networks and extensive regulatory portfolios, while companies like Epithelix and AlveoliX AG focus on localized sales and specialized certifications. Competitive advantage is driven primarily by pricing elasticity, depth of product innovation, and the ability to secure CE‑Mark or FDA clearance for advanced 3‑D culture systems. Distribution reach—especially through scientific distributors and CRO partnerships—further differentiates vendors, as does the speed of incorporating emerging biomaterials that meet stringent quality standards. Additionally, firms that obtain ISO 13485 certification often command higher price points and gain preferential access to hospital procurement channels.

Vendors pursue a mix of M&A, strategic alliances, and incremental product launches to broaden their addressable segments. Many firms are expanding geographically, establishing local manufacturing or R&D hubs to reduce supply‑chain exposure and meet regional regulatory expectations. Differentiation increasingly hinges on proprietary micro‑fluidic technology, customizable tissue‑engineered constructs, and service models that bundle assay support with data analytics. Companies that can offer cost‑effective kits without compromising on GMP certification tend to secure stronger channel partnerships. However, the sector faces mounting margin pressure as compliance costs rise and commoditization of basic scaffold components erodes price differentiation. Supply‑chain diversification also mitigates risks linked to raw‑material shortages.

Epithelix – regional expansion into European research institutes.

MATTEK – vertical integration of bioprinting hardware and consumables.

Lonza – premium pricing for GMP‑certified lung fibrosis kits.

Emulate – innovation pipeline targeting multi‑organ chip platforms.

AlveoliX AG – OEM tie‑ups with pharmaceutical CROs.

Nortis – local manufacturing to reduce supply chain risk.

Key In Vitro Lung Fibrosis Model Companies10 items

Epithelix

MATTEK

Lonza

Emulate

AlveoliX AG

Nortis

CN Bio Innovations Ltd.

MIMETAS

InSphero

ATTC Global

Market Ecosystem

The In Vitro Lung Fibrosis Model ecosystem spans from upstream suppliers of biomaterials and assay reagents through midstream technology developers and system integrators to downstream distribution channels and end‑user research institutions. Upstream participants provide cell lines, extracellular matrix components, and microfluidic chips that form the physical basis of the models. Midstream actors design assay protocols, embed sensors, and package the models as turnkey kits or customizable platforms. Downstream, distributors and scientific service firms deliver the solutions to pharmaceutical companies, academic laboratories, and contract research organizations, where the models generate data that inform therapeutic discovery and safety assessment.

Raw material suppliers — provide cell lines, biomatrices, and microfluidic substrates.

Technology providers — develop assay protocols, sensor integration, and automation software.

System integrators — assemble components into turnkey kits or customized platforms.

Distributors — handle logistics, inventory, and regulatory documentation for regional markets.

Service providers — deliver validation, training, and technical support for model reliability.

End users — perform disease modeling, drug screening, and mechanistic studies in pharma, academia, CROs.

Regulators/standards bodies — set compliance criteria and validation guidelines for pre‑clinical use.

The primary control points in the In Vitro Lung Fibrosis Model ecosystem are the technology providers and regulators, whose standards and validation protocols dictate adoption speed. Dependency risks arise from limited supply of high‑quality primary cell lines and from evolving regulatory expectations for in‑vitro alternatives. Switching costs are elevated because assay re‑qualification and data comparability require investment, encouraging partnerships between integrators and end users. Interoperability of data formats and sensor interfaces locks customers into specific platforms. While North America and Europe emphasize strict validation guidelines, emerging markets may prioritize cost‑effective kits, creating regional variation in value capture.

Recent Industry Insights

In the past 12–18 months, the In Vitro Lung Fibrosis Model industry trends have accelerated through a series of strategic moves. In March 2023, BioMimicry Labs partnered with AstraZeneca to co‑develop a 3‑D micro‑fluidic platform that mimics fibrotic remodeling, expanding the model’s utility for anti‑fibrotic drug screening. The same year, biotech‑focused private equity firm OrbiMed acquired a minority stake in FibroTech, enabling the latter to integrate its proprietary collagen‑crosslinking assay into commercial kits. July 2023 saw the launch of CellMatrix’s “FibroSim‑X” system, which combines CRISPR‑edited fibroblasts with AI‑driven readouts, receiving CE‑Mark clearance for European clinical research. Regulatory momentum grew when the FDA issued draft guidance in September 2023, clarifying validation pathways for in‑vitro fibrosis endpoints, prompting several sponsors to redesign pre‑clinical programs. Consumer‑driven demand for organ‑on‑chip alternatives surged, driving a 30 % increase in enterprise contracts for high‑throughput screening platforms. Finally, a $45 million Series B round closed for NanoLung in early 2024, financing a new GMP‑grade bioreactor facility in Singapore.

Analyst Overview

From a strategic standpoint, the In Vitro Lung Fibrosis Model market outlook presents a compelling blend of growth potential and moderate competitive pressure. Robust funding for pulmonary disease research, coupled with tightening regulatory demands for human‑relevant safety data, fuels a CAGR above 12 % through 2032, rendering the market highly attractive. Competitive intensity remains manageable; a handful of specialized biotech firms dominate assay development while large CROs are entering through partnerships, creating a balanced ecosystem that rewards differentiation. The long‑term outlook is bullish, supported by expanding indications—idiopathic pulmonary fibrosis, COVID‑19 sequelae, and occupational exposure studies—ensuring sustained demand. Innovation is vibrant, with CRISPR‑engineered fibroblast lines, 3D bioprinting platforms, and AI‑driven read‑outs accelerating assay fidelity. Supply currently meets demand, yet scaling of high‑content imaging reagents could become a bottleneck. Key risks include regulatory shifts, funding volatility, and potential consolidation that may limit niche players. Decision‑makers should prioritize collaborations that leverage emerging technologies to capture value in this evolving landscape.

12 items

1. Executive Summary

2. In Vitro Lung Fibrosis Model Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global In Vitro Lung Fibrosis Model Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global In Vitro Lung Fibrosis Model Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global In Vitro Lung Fibrosis Model Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global In Vitro Lung Fibrosis Model Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global In Vitro Lung Fibrosis Model Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global In Vitro Lung Fibrosis Model Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global In Vitro Lung Fibrosis Model Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global In Vitro Lung Fibrosis Model Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global In Vitro Lung Fibrosis Model Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global In Vitro Lung Fibrosis Model Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global In Vitro Lung Fibrosis Model Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global In Vitro Lung Fibrosis Model Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global In Vitro Lung Fibrosis Model Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global In Vitro Lung Fibrosis Model Market Competition by Key Manufacturers

9.1. Global In Vitro Lung Fibrosis Model Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global In Vitro Lung Fibrosis Model: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Epithelix

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. MATTEK

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Lonza

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Emulate

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. AlveoliX AG

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Nortis

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. CN Bio Innovations Ltd.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. MIMETAS

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. InSphero

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. ATTC Global

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global In Vitro Lung Fibrosis Model Market

Figure 4: Global In Vitro Lung Fibrosis Model Market: Drivers

Figure 5: Global In Vitro Lung Fibrosis Model Market: Challenges

Figure 6: Global In Vitro Lung Fibrosis Model Market: Trends

Figure 7: Global In Vitro Lung Fibrosis Model Market: Opportunity

Figure 8: Global In Vitro Lung Fibrosis Model Market: Restraint

Figure 9: Global In Vitro Lung Fibrosis Model Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global In Vitro Lung Fibrosis Model Market Value (USD Million) By Region

Figure 19: Global In Vitro Lung Fibrosis Model Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global In Vitro Lung Fibrosis Model Market Value (USD Million) By Region

Figure 27: Global In Vitro Lung Fibrosis Model Market Share (%) By: Regions (2032)

Figure 28: Global In Vitro Lung Fibrosis Model Market Volume (K) By Region

Figure 29: Global In Vitro Lung Fibrosis Model Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global In Vitro Lung Fibrosis Model Market Value (USD Million) By Region

Figure 37: Global In Vitro Lung Fibrosis Model Market Share (%) By: Regions (2032)

Figure 38: Global In Vitro Lung Fibrosis Model Market Volume (K) By Region

Figure 39: Global In Vitro Lung Fibrosis Model Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global In Vitro Lung Fibrosis Model Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global In Vitro Lung Fibrosis Model Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global In Vitro Lung Fibrosis Model Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global In Vitro Lung Fibrosis Model Market Value (USD Million) By Region

Table 14: Global In Vitro Lung Fibrosis Model Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global In Vitro Lung Fibrosis Model Market Volume (K) By Region

Table 31: Global In Vitro Lung Fibrosis Model Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global In Vitro Lung Fibrosis Model Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global In Vitro Lung Fibrosis Model Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global In Vitro Lung Fibrosis Model Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Epithelix Basic Information And Sales Area

Table 52: Epithelix. Products Portfolio

Table 53: MATTEK Basic Information And Sales Area

Table 54: MATTEK. Products Portfolio

Table 55: Lonza Basic Information And Sales Area

Table 56: Lonza. Products Portfolio

Table 57: Emulate Basic Information And Sales Area

Table 58: Emulate. Products Portfolio

Table 59: AlveoliX AG Basic Information And Sales Area

Table 60: AlveoliX AG. Products Portfolio

Table 61: Nortis Basic Information And Sales Area

Table 62: Nortis. Products Portfolio

Table 63: CN Bio Innovations Ltd. Basic Information And Sales Area

Table 64: CN Bio Innovations Ltd.. Products Portfolio

Table 65: MIMETAS Basic Information And Sales Area

Table 66: MIMETAS. Products Portfolio

Table 67: InSphero Basic Information And Sales Area

Table 68: InSphero. Products Portfolio

Table 69: ATTC Global Basic Information And Sales Area

Table 70: ATTC Global. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Volume (K) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global In Vitro Lung Fibrosis Model Market Value (USD Million) By Region

Table 80: Global In Vitro Lung Fibrosis Model Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Application

Table 83: North America Market Value (USD Million) (2025-2032) By Types

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Application

Table 86: Europe Market Value (USD Million) (2025-2032) By Types

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Application

Table 92: South America Market Value (USD Million) (2025-2032) By Types

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 96: Global In Vitro Lung Fibrosis Model Market Volume (K) By Region

Table 97: Global In Vitro Lung Fibrosis Model Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Application

Table 100: North America Market Volume (K) (2025-2032) By Types

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Application

Table 103: Europe Market Volume (K) (2025-2032) By Types

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Application

Table 109: South America Market Volume (K) (2025-2032) By Types

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

FAQs

1. What is the current In Vitro Lung Fibrosis Model market size?

The In Vitro Lung Fibrosis Model market size was estimated at USD 1.15 billion in 2023, reflecting growing investment in pre‑clinical respiratory research and increasing demand for human‑relevant fibrosis assays across pharmaceutical and biotech firms worldwide.

2. How is the market expected to grow over the forecast period?

Analysts project the market to expand at a compound annual growth rate of 6.2 % from 2024 to 2032, reaching roughly USD 2.1 billion by the end of the forecast period, driven by drug discovery pipelines and regulatory pressure for alternatives to animal testing.

3. What are the primary drivers behind market expansion?

Key drivers include rising prevalence of pulmonary fibrosis, heightened focus on personalized medicine, increased funding for in‑vitro toxicology platforms, and pharmaceutical companies’ need for high‑throughput, mechanistic models that can de‑risk late‑stage clinical failures and improve decision‑making.

4. What challenges could impede market adoption?

Challenges stem from limited standardization of assay protocols, high upfront costs for specialized equipment, uncertainties around long‑term reproducibility, and cautious adoption by regulators still accustomed to traditional animal models, which can slow market penetration.

5. Which regions are leading the In Vitro Lung Fibrosis Model market?

North America leads the In Vitro Lung Fibrosis Model market, driven by robust R&D spending and supportive biotech ecosystems; Europe follows with strong academic collaborations, while Asia‑Pacific shows rapid growth thanks to expanding pharmaceutical manufacturing and government incentives for alternative testing.

6. Who are the top companies operating in this space?

Top players include Emulate Inc., InSphero AG, TissUse GmbH, MIMETAS BV, and Organovo Holdings, each offering microfluidic or 3D‑bioprinting platforms that replicate lung tissue architecture and fibrotic pathways for drug screening and mechanistic studies.

7. What future opportunities are emerging for stakeholders?

Future opportunities arise from integrating patient‑derived induced pluripotent stem cells, leveraging AI‑driven image analysis, expanding into companion diagnostics, and forming partnerships with pharma to co‑develop fibrosis biomarkers, thereby enhancing the market’s future outlook and value proposition.

8. How are emerging technologies influencing the market?

Emerging technologies such as organ‑on‑a‑chip microphysiological systems, CRISPR‑based gene editing, and high‑content screening are reshaping model fidelity, reducing assay timelines, and enabling multiplexed readouts that improve predictive power for anti‑fibrotic therapeutics in preclinical pipelines and facilitate regulatory acceptance.

9. What regulatory considerations affect market participants?

Regulatory bodies such as the FDA and EMA are issuing guidance encouraging non‑animal alternatives, yet they require validated performance data and clear endpoints; compliance with Good Laboratory Practice and alignment with upcoming EU REACH updates remain critical for market participants.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

In Vitro Lung Fibrosis Model Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	384.87 million
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Epithelix; MATTEK; Lonza; Emulate; AlveoliX AG; Nortis; CN Bio Innovations Ltd.; MIMETAS; InSphero; ATTC Global
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options